CompletedPhase 3NCT01979952
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boehringer Ingelheim
- Principal Investigator
- Boehringer IngelheimBoehringer Ingelheim
- Intervention
- Matching Placebo(drug)
- Enrollment
- 113 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2013 – 2016
Study locations (25)
- Western CT Medical Group, P.C., Danbury, Connecticut, United States
- Clinical Research Center Sarasota Memorial Hosptial, Sarasota, Florida, United States
- Chest Medicine Clinical Services, Skokie, Illinois, United States
- Baptist Health Lexington, Lexington, Kentucky, United States
- Minnesota Lung Research, Minneapolis, Minnesota, United States
- Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Winthrop University Hospital, Mineola, New York, United States
- ID Clinical Research, LTD, Toledo, Ohio, United States
- The Oregon Clinic, Portland, Oregon, United States
- Lowcountry Lung and Crit Care, Charleston, South Carolina, United States
- Annette C & Harold C Simmons Transplant Institute, Dallas, Texas, United States
- University of Alberta Hospital (University of Alberta), Edmonton, Alberta, Canada
- Vancouver General Hospital, Vancouver, British Columbia, Canada
- St. Paul's Hospital, Vancouver, British Columbia, Canada
- Concordia Hospital, Winnipeg, Manitoba, Canada
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01979952 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics